Armistice Capital’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Armistice Capital’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,268,000	Closed	-$9.14M	–	105
2019 Q4	$9.14M	Buy	2,268,000 +696,000	+44%	+$2.41M	0.53%	49
2019 Q3	$6.79M	Sell	1,572,000 -906,000	-37%	-$3.62M	0.45%	49
2019 Q2	$9.89M	Buy	2,478,000 +354,000	+17%	+$1.68M	0.62%	36
2019 Q1	$11.4M	Buy	2,124,000 +156,000	+8%	+$1.01M	0.62%	38
2018 Q4	$10.1M	Buy	1,968,000 +768,000	+64%	+$5.83M	0.77%	31
2018 Q3	$11.6M	Buy	1,200,000 +68,000	+6%	+$686K	0.7%	41
2018 Q2	$11.5M	Buy	1,132,000 +552,000	+95%	+$6.25M	0.75%	42
2018 Q1	$7.54M	Buy	+580,000	New	+$8.64M	0.58%	46

Other funds holding PRTK

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Armistice Capital's PRTK Position: Q1 2020 in Review

Armistice Capital sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2020, closing a stake of 2,268,000 shares — an estimated $9.14M sold.

Armistice Capital first reported a position in PRTK in Q1 2018 and held it in 8 quarters. The position peaked at $11.6M in Q3 2018. 85 funds tracked by Wall St. Rank hold PRTK as of Q1 2020.

Armistice Capital reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Armistice Capital sold 2,268,000 Paratek Pharmaceuticals, Inc. shares in Q1 2020, an estimated $9.14M.
Armistice Capital first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2018 and held it in 8 quarters.
Armistice Capital's Paratek Pharmaceuticals, Inc. position peaked at $11.6M in Q3 2018.
85 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2020.

Based on Armistice Capital's 13F filing for Q1 2020, filed 15 May 2020.